https://novapharmanews.com/apac/news/pmda-approves-new-pharmaceuticals-medical-devices-whats-new 2026-06-03T06:37:30.226Z NovaPharmaNews en 2026-06-03T03:09:14.935Z PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/uploads/articles/pmda-approves-new-pharmaceuticals-medical-devices-whats-new.webp PMDA Approves New Pharmaceuticals and Medical Devices: What's New https://novapharmanews.com/eu/news/eu-trade-policy-china-pharma-analysis 2026-06-03T06:29:31.717Z NovaPharmaNews en 2026-06-03T03:03:08.551Z EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/uploads/articles/eu-trade-policy-china-pharma-analysis.webp EU Bolsters Trade Defenses Against Chinese Imports: A Pharmaceutical Market Analysis https://novapharmanews.com/eu/news/ema-january-drug-approvals-2025 2026-06-03T05:48:21.968Z NovaPharmaNews en 2026-06-03T02:53:30.934Z EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/uploads/articles/ema-january-drug-approvals-2025.webp EMA Approves New Medicines in January: Key Updates for Pharma Investors and BD Teams https://novapharmanews.com/eu/news/chmp-drug-approvals-analysis 2026-06-03T05:33:45.014Z NovaPharmaNews en 2026-06-03T02:48:00.650Z CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/uploads/articles/chmp-drug-approvals-analysis.webp CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry https://novapharmanews.com/us/news/munck-wilson-mandala-fort-worth-life-sciences-expansion 2026-06-03T06:39:01.743Z NovaPharmaNews en 2026-06-03T02:44:01.027Z Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/uploads/articles/munck-wilson-mandala-fort-worth-life-sciences-expansion.webp Munck Wilson Mandala Expands to Fort Worth, Taps Life Sciences Leader https://novapharmanews.com/us/news/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation 2026-06-03T06:39:00.271Z NovaPharmaNews en 2026-06-03T02:40:41.950Z Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation sickle cell disease https://novapharmanews.com/uploads/articles/fulcrum-therapeutics-stock-plunges-sickle-cell-drug-discontinuation.webp Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation https://novapharmanews.com/us/news/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s 2026-06-03T06:39:03.340Z NovaPharmaNews en 2026-06-03T02:39:08.229Z Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. mpox https://novapharmanews.com/uploads/articles/senior-nih-scientist-research-fellow-charged-with-bringing-deactivated-mpox-virus-into-u-s.webp Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S. https://novapharmanews.com/us/news/cambridge-biotech-merger-acquisition-market-analysis 2026-06-03T05:33:53.024Z NovaPharmaNews en 2026-06-03T02:37:12.765Z Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures sickle cell https://novapharmanews.com/uploads/articles/cambridge-biotech-merger-acquisition-market-analysis.webp Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures https://novapharmanews.com/us/news/outlook-therapeutics-lytenava-fda-resubmission-60-day-review 2026-06-03T05:33:55.102Z NovaPharmaNews en 2026-06-03T02:07:31.338Z Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review LYTENAVA https://novapharmanews.com/uploads/articles/outlook-therapeutics-lytenava-fda-resubmission-60-day-review.webp Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review https://novapharmanews.com/us/news/hanmi-signs-licensing-deal-lilly-sonefpeglutide 2026-06-03T05:34:00.201Z NovaPharmaNews en 2026-06-03T01:55:24.362Z Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline sonefpeglutide https://novapharmanews.com/uploads/articles/hanmi-signs-licensing-deal-lilly-sonefpeglutide.webp Hanmi Signs Licensing Deal with Eli Lilly for Sonefpeglutide, Bolstering GLP-2 Pipeline https://novapharmanews.com/us/news/fda-final-guidance-pulmonary-tuberculosis-drug-development 2026-06-03T05:33:59.235Z NovaPharmaNews en 2026-06-03T01:49:47.494Z FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development pulmonary tuberculosis https://novapharmanews.com/uploads/articles/fda-final-guidance-pulmonary-tuberculosis-drug-development.webp FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development https://novapharmanews.com/us/news/stat-pharmalittle-lilly-340b-ebola-vaccine-funding 2026-06-03T05:57:16.178Z NovaPharmaNews en 2026-06-02T19:37:04.227Z STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More Ebola https://novapharmanews.com/uploads/articles/stat-pharmalittle-lilly-340b-ebola-vaccine-funding.webp STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More https://novapharmanews.com/us/news/why-us-manufactured-pharmaceutical-packaging-equipment-matters 2026-06-03T05:34:03.035Z NovaPharmaNews en 2026-06-02T16:23:39.037Z Why US-manufactured pharmaceutical packaging equipment matters https://novapharmanews.com/uploads/articles/why-us-manufactured-pharmaceutical-packaging-equipment-matters.webp Why US-manufactured pharmaceutical packaging equipment matters https://novapharmanews.com/us/news/virtual-end-doctors-office-waiting-room 2026-06-03T05:34:05.050Z NovaPharmaNews en 2026-06-02T16:23:38.039Z Opinion: The Virtual End of the Doctor's Office Waiting Room https://novapharmanews.com/uploads/articles/virtual-end-doctors-office-waiting-room.webp Opinion: The Virtual End of the Doctor's Office Waiting Room https://novapharmanews.com/us/news/how-one-state-s-medical-meal-program-lowered-health-care-costs 2026-06-03T05:34:07.053Z NovaPharmaNews en 2026-06-02T16:23:37.423Z How one state’s medical meal program lowered health care costs Ebola vaccine https://novapharmanews.com/uploads/articles/how-one-state-s-medical-meal-program-lowered-health-care-costs.webp How one state’s medical meal program lowered health care costs https://novapharmanews.com/us/news/stat-corporate-medicine-telehealth-crackdown 2026-06-03T05:43:01.744Z NovaPharmaNews en 2026-06-02T12:28:43.909Z STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/uploads/articles/stat-corporate-medicine-telehealth-crackdown.webp STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models https://novapharmanews.com/apac/news/global-rwe-guidance-regulatory-decision-making-updates 2026-06-03T05:34:17.868Z NovaPharmaNews en 2026-06-02T03:53:12.249Z Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/uploads/articles/global-rwe-guidance-regulatory-decision-making-updates.webp Global Regulatory Agencies Update Real-World Evidence Guidance for Decision-Making https://novapharmanews.com/apac/news/china-oncology-research-europe-alarm 2026-06-03T05:34:13.054Z NovaPharmaNews en 2026-06-02T03:48:14.665Z China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge oncology, cancer https://novapharmanews.com/uploads/articles/china-oncology-research-europe-alarm.webp China's Ascendancy in Oncology Research Alarms European Oncologists, Threatening Europe's Competitive Edge https://novapharmanews.com/apac/news/asco-2026-asian-oncology-innovation-clinical-trials 2026-06-03T06:13:12.021Z NovaPharmaNews en 2026-06-02T03:39:08.824Z ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements oncology https://novapharmanews.com/uploads/articles/asco-2026-asian-oncology-innovation-clinical-trials.webp ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements https://novapharmanews.com/us/news/lilly-gilead-pharma-ma-boom-market-analysis 2026-06-03T06:10:19.397Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis cancer https://novapharmanews.com/uploads/articles/lilly-gilead-pharma-ma-boom-market-analysis.webp Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis https://novapharmanews.com/eu/news/x4-pharmaceuticals-mavorixafor-ema-approval 2026-06-03T05:34:23.109Z NovaPharmaNews en 2026-06-02T03:29:11.653Z X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome Mavorixafor https://novapharmanews.com/uploads/articles/x4-pharmaceuticals-mavorixafor-ema-approval.webp X4 Pharmaceuticals' Mavorixafor Receives EMA Approval Recommendation for WHIM Syndrome https://novapharmanews.com/eu/news/mayer-brown-serb-pharmaceuticals-idefirix-acquisition 2026-06-03T05:34:19.122Z NovaPharmaNews en 2026-06-02T03:29:11.653Z SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB Idefirix, imlifidase https://novapharmanews.com/uploads/articles/mayer-brown-serb-pharmaceuticals-idefirix-acquisition.webp SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB https://novapharmanews.com/us/news/fda-approves-atezolizumab-ctdna-mrd-positive-mibc 2026-06-03T05:34:21.105Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy atezolizumab, muscle invasive bladder cancer https://novapharmanews.com/uploads/articles/fda-approves-atezolizumab-ctdna-mrd-positive-mibc.webp FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy https://novapharmanews.com/us/news/inventiva-leadership-lanifibranor-phase-3-data 2026-06-03T05:34:25.120Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data lanifibranor https://novapharmanews.com/uploads/articles/inventiva-leadership-lanifibranor-phase-3-data.webp Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data https://novapharmanews.com/us/news/fda-draft-guidance-biosimilar-pk-studies 2026-06-03T05:34:29.110Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/uploads/articles/fda-draft-guidance-biosimilar-pk-studies.webp FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry https://novapharmanews.com/us/news/new-fda-approach-drug-prices-implications 2026-06-03T05:34:43.128Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/uploads/articles/new-fda-approach-drug-prices-implications.webp FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy https://novapharmanews.com/eu/news/fda-approves-aldosterone-synthase-inhibitor-hypertension 2026-06-03T05:34:45.154Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension baxdrostat, Baxfendy, hypertension https://novapharmanews.com/uploads/articles/fda-approves-aldosterone-synthase-inhibitor-hypertension.webp FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension https://novapharmanews.com/apac/news/beone-medicines-phase-3-herizon-gea-data-nejm 2026-06-03T06:12:40.318Z NovaPharmaNews en 2026-06-02T03:29:11.653Z BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/uploads/articles/beone-medicines-phase-3-herizon-gea-data-nejm.webp BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors https://novapharmanews.com/apac/news/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit 2026-06-03T05:34:37.116Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/uploads/articles/dishman-carbogen-amcis-shanghai-nmpa-gmp-audit.webp Dishman Carbogen Amcis Shanghai Site Achieves NMPA GMP Compliance with Zero Findings https://novapharmanews.com/apac/news/newron-pharmaceuticals-june-investor-conferences 2026-06-03T05:34:31.113Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/uploads/articles/newron-pharmaceuticals-june-investor-conferences.webp Newron Pharmaceuticals to Present at Upcoming Investor Conferences https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-06-03T05:34:17.059Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications https://novapharmanews.com/apac/news/hong-kong-new-drug-approval-process 2026-06-03T05:34:43.901Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/uploads/articles/hong-kong-new-drug-approval-process.webp Hong Kong Overhauls Drug Approval Process: What Pharma BD Teams Need to Know https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-06-03T06:09:01.377Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Outlines 2026 Strategy and Partnership Focus https://novapharmanews.com/eu/news/datroway-priority-review-metastatic-tnbc 2026-06-03T05:34:39.125Z NovaPharmaNews en 2026-06-02T03:29:11.653Z Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients Datroway, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-priority-review-metastatic-tnbc.webp Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients https://novapharmanews.com/us/news/fda-expands-market-access-ends-products 2026-06-03T05:34:35.114Z NovaPharmaNews en 2026-06-02T03:29:11.653Z FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/uploads/articles/fda-expands-market-access-ends-products.webp FDA Expands ENDS Market Access: Implications for Pharma BD and Investors https://novapharmanews.com/eu/news/ema-implements-new-eu-pharma-rules-regulatory-updates 2026-06-03T05:34:52.329Z NovaPharmaNews en 2026-06-02T03:27:44.113Z EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/uploads/articles/ema-implements-new-eu-pharma-rules-regulatory-updates.webp EMA Initiates Implementation of New EU Pharmaceutical Legislation: What Pharma Needs to Know https://novapharmanews.com/eu/news/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim 2026-06-03T05:34:51.142Z NovaPharmaNews en 2026-06-02T03:20:47.528Z Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment eye drug https://novapharmanews.com/uploads/articles/regeneron-pharma-ema-eye-drug-review-wolfe-target-trim.webp Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment https://novapharmanews.com/eu/news/teva-olanzapine-lai-ema-review-schizophrenia 2026-06-03T05:34:53.189Z NovaPharmaNews en 2026-06-02T03:17:52.479Z Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option olanzapine, schizophrenia https://novapharmanews.com/uploads/articles/teva-olanzapine-lai-ema-review-schizophrenia.webp Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option https://novapharmanews.com/eu/news/asco-2026-european-pharma-astrazeneca-roche-market-analysis 2026-06-03T05:34:55.514Z NovaPharmaNews en 2026-06-02T03:10:06.470Z ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/uploads/articles/asco-2026-european-pharma-astrazeneca-roche-market-analysis.webp ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address https://novapharmanews.com/eu/news/esmo-2025-nmi-bladder-cancer-highlights 2026-06-03T05:34:57.225Z NovaPharmaNews en 2026-06-02T03:05:38.541Z ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/esmo-2025-nmi-bladder-cancer-highlights.webp ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies https://novapharmanews.com/eu/news/datroway-trodelvy-first-line-tnbc-battle 2026-06-03T05:34:59.155Z NovaPharmaNews en 2026-06-02T03:00:26.076Z Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape Datroway, Trodelvy, oncology, breast cancer https://novapharmanews.com/uploads/articles/datroway-trodelvy-first-line-tnbc-battle.webp Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape https://novapharmanews.com/us/news/citius-pharmaceuticals-stock-update-cancer-anti-infective 2026-06-03T05:35:01.171Z NovaPharmaNews en 2026-06-02T02:57:43.611Z Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights cancer, anti-infective https://novapharmanews.com/uploads/articles/citius-pharmaceuticals-stock-update-cancer-anti-infective.webp Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights https://novapharmanews.com/eu/news/idorsia-c-diff-vaccine-clinical-progress 2026-06-03T05:35:03.153Z NovaPharmaNews en 2026-06-02T02:47:49.435Z Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress IDOR-1134-2831, Clostridioides difficile infection https://novapharmanews.com/uploads/articles/idorsia-c-diff-vaccine-clinical-progress.webp Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress https://novapharmanews.com/us/news/fda-guidance-animal-thyroid-products-august-2026 2026-06-03T05:35:05.161Z NovaPharmaNews en 2026-06-02T02:35:54.944Z FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift NP Thyroid, Desiccated Thyroid Extract, Graves' Disease https://novapharmanews.com/uploads/articles/fda-guidance-animal-thyroid-products-august-2026.webp FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift https://novapharmanews.com/us/news/global-regulatory-roundup-june-1-2026 2026-06-03T05:35:07.172Z NovaPharmaNews en 2026-06-02T02:31:43.284Z Global Regulatory Roundup: Key Updates for June 1, 2026 Dermatologicals, oncology, Neurological, Rare Diseases https://novapharmanews.com/uploads/articles/global-regulatory-roundup-june-1-2026.webp Global Regulatory Roundup: Key Updates for June 1, 2026 https://novapharmanews.com/us/news/biotech-m-and-a-trends-2026-outlook 2026-06-03T05:35:09.171Z NovaPharmaNews en 2026-06-02T02:27:52.983Z Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/uploads/articles/biotech-m-and-a-trends-2026-outlook.webp Biotech M&A Trends: Navigating the 2026 Outlook for Strategic Growth https://novapharmanews.com/us/news/big-pharma-small-deals-biotech-boon 2026-06-03T06:14:43.602Z NovaPharmaNews en 2026-06-02T02:21:10.753Z Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/uploads/articles/big-pharma-small-deals-biotech-boon.webp Big Pharma's Shift to Smaller Deals Boosts Biotech Sector https://novapharmanews.com/us/news/rallybio-avenzo-reverse-merger-oncology-deal 2026-06-03T05:35:16.953Z NovaPharmaNews en 2026-06-02T02:18:08.248Z Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/uploads/articles/rallybio-avenzo-reverse-merger-oncology-deal.webp Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline https://novapharmanews.com/us/news/legend-biotech-asco-data-carvykti-lb2102 2026-06-03T05:35:15.166Z NovaPharmaNews en 2026-06-02T02:06:25.818Z Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO LB2102, CARVYKTI https://novapharmanews.com/uploads/articles/legend-biotech-asco-data-carvykti-lb2102.webp Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO https://novapharmanews.com/us/news/cdc-ebola-containment-clinical-trials-priority 2026-06-03T05:35:19.072Z NovaPharmaNews en 2026-06-02T02:01:43.120Z CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials Ebola https://novapharmanews.com/uploads/articles/cdc-ebola-containment-clinical-trials-priority.webp CDC Prioritizes Ebola Containment, Highlighting Critical Role of Clinical Trials https://novapharmanews.com/us/news/asia-biopharma-innovation-epicenter-drug-approvals 2026-06-03T05:35:19.188Z NovaPharmaNews en 2026-06-02T01:50:57.481Z Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/uploads/articles/asia-biopharma-innovation-epicenter-drug-approvals.webp Asia Surges as Biopharma Innovation Hub, Driving Global Drug Approvals https://novapharmanews.com/us/news/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research 2026-06-03T06:38:58.660Z NovaPharmaNews en 2026-06-02T01:47:13.789Z DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/uploads/articles/dea-reschedules-marijuana-schedule-iii-expediting-medical-access-research.webp DEA Reschedules Marijuana to Schedule III, Expediting Medical Access and Research https://novapharmanews.com/us/news/fda-expert-panel-review-peptide-access-compounded-drug-market 2026-06-03T05:35:27.360Z NovaPharmaNews en 2026-06-02T01:42:09.232Z FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/uploads/articles/fda-expert-panel-review-peptide-access-compounded-drug-market.webp FDA Expert Panel to Review Peptide Access, Impacting Compounded Drug Market https://novapharmanews.com/us/news/elite-pharma-fda-anda-generic-anticoagulant-26b 2026-06-03T06:34:23.575Z NovaPharmaNews en 2026-06-02T01:32:47.226Z Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market blood thinner https://novapharmanews.com/uploads/articles/elite-pharma-fda-anda-generic-anticoagulant-26b.webp Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market https://novapharmanews.com/us/news/cms-finalizes-medicaid-work-requirement-rules 2026-06-03T05:35:27.203Z NovaPharmaNews en 2026-06-02T01:22:36.164Z CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/uploads/articles/cms-finalizes-medicaid-work-requirement-rules.webp CMS Finalizes Medicaid Work Requirement Rules, Impacting State Programs and Pharma Strategy https://novapharmanews.com/us/news/medicus-pharma-biotech-showcase-2026 2026-06-03T05:35:29.186Z NovaPharmaNews en 2026-06-01T23:38:28.408Z Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program https://novapharmanews.com/uploads/articles/medicus-pharma-biotech-showcase-2026.webp Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program https://novapharmanews.com/us/news/rigel-pharmaceuticals-licenses-veppanu 2026-06-03T05:35:31.176Z NovaPharmaNews en 2026-06-01T22:23:48.621Z Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU VEPPANU, breast cancer https://novapharmanews.com/uploads/articles/rigel-pharmaceuticals-licenses-veppanu.webp Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU https://novapharmanews.com/us/news/fda-ai-clinical-trials-rfi-guide 2026-06-03T06:18:32.780Z NovaPharmaNews en 2026-06-01T21:30:56.231Z Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide https://novapharmanews.com/uploads/articles/fda-ai-clinical-trials-rfi-guide.webp Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide https://novapharmanews.com/apac/news/estado-actual-y-acciones-para-impulsar-la-investigacion-clinica-en-mexico-2025-5b7db092 2026-06-03T05:35:35.194Z NovaPharmaNews en 2026-06-01T21:10:53.755Z Estado Actual y Acciones para Impulsar la Investigación Clínica en México: 2025 https://novapharmanews.com/uploads/articles/estado-actual-y-acciones-para-impulsar-la-investigacion-clinica-en-mexico-2025-5b7db092.webp Estado Actual y Acciones para Impulsar la Investigación Clínica en México: 2025 https://novapharmanews.com/us/news/formycon-ag-geschaftsbericht-2025-5ff7fa30 2026-06-03T05:35:41.247Z NovaPharmaNews en 2026-06-01T21:04:54.385Z Formycon AG Geschäftsbericht 2025: Key Insights and Implications https://novapharmanews.com/uploads/articles/formycon-ag-geschaftsbericht-2025-5ff7fa30.webp Formycon AG Geschäftsbericht 2025: Key Insights and Implications